urgency urinary incontinence episodes

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14

OnabotulinumtoxinA 200 U produced a greater 6-month mean reduction in daily urgency incontinence episodes than sacral neuromodulation (-3.9 vs -3.3 episodes per day; mean difference, 0.63; 95% CI, 0.1

Effect: improvement; mean difference, 0.63 episodes per day; CI: 95% CI, 0.13 to 1.14